Analytical Method Lifecycle: A Roadmap for Biopharmaceutical Development - The authors propose a roadmap for analytical lifecycle development. - BioPharm International


Analytical Method Lifecycle: A Roadmap for Biopharmaceutical Development
The authors propose a roadmap for analytical lifecycle development.

BioPharm International
Volume 26, Issue 4, pp. 46-50


Analytical method lifecycle is a continuous process that improves and documents the understanding of the capabilities of each analytical method used throughout the clinical development of a new drug candidate. Of key importance, analytical lifecycle-related activities have to be appropriately staged in accordance with the regulatory requirements without neglecting the financial and time constraints incurred by each project. Currently, regulatory requirements for analytical methods are primarily directed at prerequisites for commercial manufacturing, the end point of the development process, without any description of requirements regarding the stepwise development leading to validation. This article proposes an analytical lifecycle roadmap that will stage the various steps involved in analytical method development while attempting to meet the expectations of the stakeholders involved in the management of project risk, development costs, and regulatory compliance.

Photo Credit: Getty, Design Pics/Bilderbuch
Despite the growing quality-by-design (QbD) trends that promote accumulating characterization data from early clinical development, a number of biotech companies are constrained to demonstrate early positive clinical results within a shorter timeframe and with less money than before. Often, these companies have a business model to sell or license the product under clinical development to a larger pharmaceutical company for final development and marketing. The value of the product will then be determined by a number of factors including indication, product safety/efficacy data, and process development status.

Table I: Project overview in clinical development.
Biotech and pharmaceutical companies involved in the process development and clinical manufacturing of a new biologic drug candidate have to achieve the right balance between development goals and inherent project risk, cost, and regulatory compliance at the different stages of clinical development (see Table I). The development strategy should therefore rely on phase-dependent yet flexible business decisions that take into account all the elements of risk mitigation, cost balance, and compliance towards regulatory requirements, an approach that will of course affect the different aspects of analytical work. In this context, a lifecycle approach has the benefit of offering a long-term vision of the project associated with sustainable business decisions to the stakeholders involved.

Analytical method lifecycle refers to the combined activities of analytical method development, improvement, qualification, validation, transfer, and maintenance related to GMP production. An integrated approach to analytical lifecycle must ensure that analytical methods evolve from initial development to commercial use in a manner that is best suited for their intended use at the various clinical stages on the way to commercialization. Building an analytical lifecycle roadmap that satisfies all requirements must be supported by strong technical expertise as well as sound business and regulatory knowledge.

blog comments powered by Disqus



Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here